IP Library Patent Application 16769964
Patent Application
App. No. 16/769,964

SPRAY-DRIED SIALYLLACTOSE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/769,964
Abstract

Disclosed is a method for the manufacture of a spray-dried powder consisting essentially of 3′-SL and/or 6′-SL, the spray-dried powder, its use for the manufacture of nutritional compositions, and nutritional compositions containing the spray-dried powder.

Claims (26)

1 . A spray-dried powder comprising or consisting essentially of 3′-SL and/or 6′-SL which has been produced by microbial fermentation.

2 . The spray-dried powder according to claim 1 , wherein the spray-dried powder comprises at least 80%-wt., at least 85%-wt., at least 90%-wt., at least 93%-wt., at least 95%-wt. or at least 98%-wt. 3′-SL and/or 6′-SL.

3 . The spray-dried powder according to claim 1 , wherein the 3′-SL and/or 6′-SL is present in amorphous form.

4 . The spray-dried powder according to claim 1 , wherein the spray-dried powder contains comprises 15%-wt. of water, optionally 10%-wt. of water, optionally 7%-wt. of water, optionally 5%-wt. of water.

5 . The spray-dried powder according to claim 1 , wherein the spray-dried powder is free of genetically-engineered microorganisms and nucleic acid molecules derived from genetically-engineered microorganisms.

6 . A process for the manufacture of a spray-dried powder as defined in claim 1 , the process comprises:

a) purifying the 3′-SL and/or 6′-SL from a fermentation broth;

b) providing an aqueous solution containing the 3′-SL and/or 6′-SL of a); and

c) subjecting the solution of b) to spray-drying.

7 . The process according to claim 6 , wherein the purifying the 3′-SL and/or 6′-SL from a fermentation broth a) includes one or more of

i) removing the microbial cells from the fermentation broth to obtain a cleared process stream;

ii) subjecting the cleared process stream to at least one ultrafiltration;

iii) treating the cleared process stream at least one time with a cation exchange resin and/or at least one time with an anion exchange resin;

iv) subjecting the cleared process stream to at least one nanofiltration and/or diafiltration;

v) subjecting the cleared process stream to at least one electrodialysis;

vi) treating the cleared process stream at least one time with activated charcoal; and/or

vii) subjecting the cleared process stream at least one time to a crystallization and/or precipitation.

8 . The process according to claim 6 , wherein the aqueous solution contains the 3′-SL and/or 6′-SL in an amount of at least 20% (w/v), 30% (w/v), 35 (w/v), and up to 45% (w/v), 50% (w/v), 60% (w/v).

9 . The process according to claim 6 , wherein the aqueous solution containing 3′-SL and/or 6′-SL is spray-dried at a nozzle temperature of at least 110° C., optionally at least 120° C., more optionally at least 125° C., and less than 150° C., optionally less than 140° C. and more optionally less than 135° C.

10 . The process according to claim 6 , wherein the aqueous solution containing 3′-SL and/or 6′-SL is spray-dried at an outlet temperature of at least 60° C., optionally at least 65° C., and less than 80° C., optionally less than 70° C.

11 . A product comprising the spray-dried powder according to claim 1 for manufacture of a nutritional composition, optionally an infant formula.

12 . A nutritional composition containing the spray-dried powder according to claim 1 .

13 . The nutritional composition according to claim 12 , further comprising at least one additional HMO, wherein said at least one additional HMO is a neutral HMO or a sialylated HMO.

14 . The nutritional composition according to claim 12 , wherein the at least one neutral HMO is selected from the group consisting of 2′-fucosyllactose, 3-fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose and lacto-N-fucopentaose I.

15 . The nutritional composition according to claim 12 , wherein the at least one sialylated HMO is selected from the group consisting of 3′-sialyllactose, 6′-sialyllactose, sialyllacto-N-tetraose (LST)-a, LST-b, LST-c and disialyllacto-N-tetraose.

16 . The nutritional composition according to claim 12 , wherein the nutritional composition comprises at least one probiotic microorganism.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2025
From: CHR. HANSEN HMO GMBH
To: CHR. HANSEN A/S
Reel/Frame 070396/0299 →
CHANGE OF NAME Recorded Apr 6, 2022
From: JENNEWEIN BIOTECHNOLOGIE GMBH
To: CHR. HANSEN HMO GMBH
Reel/Frame 059617/0804 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2020
From: JENNEWEIN, STEFAN
To: JENNEWEIN BIOTECHNOLOGIE GMBH
Reel/Frame 053465/0960 →